Date: 11/25/2008
By JIM SUHR
Associated Press Writer
EAST ST. LOUIS, Ill. (AP) _ A widow whose husband died at a Veterans Affairs hospital under fire for substandard care has agreed to settle her lawsuit against the government for $975,000, her attorney said.
Katrina Shank had sought $12 million in her federal wrongful-death lawsuit. Her husband, 50-year-old Robert Shank III of Murray, Ky., bled to death in August 2007, a day after undergoing gallbladder surgery at the VA hospital in Marion, Ill.
Shank’s widow claimed the government failed to sufficiently check the background of her husband’s surgeon, Dr. Jose Veizaga-Mendez, before hiring him in January 2006.
Veizaga-Mendez resigned three days after Robert Shank’s death, and major surgeries were ordered halted there after inspectors attributed several patient deaths to questionable surgical care.
Terms involving Katrina Shank’s settlement were not disclosed in court documents, though an e-mail to The Associated Press by one of her attorneys, Stan Heller, put the amount at $975,000.
A message seeking comment was left Tuesday with spokesman for the national VA. According to an order by U.S. District Judge J. Phil Gilbert, the settlement becomes final after 90 days unless it hits a snag.
The VA found at least nine deaths between October 2006 and March 2007 were “directly attributable” to substandard care at the hospital. Those deaths did not include Robert Shank, who died months later.
The VA’s findings do not put the sole blame on Veizaga-Mendez, but Shank’s lawsuit said many or all of those who died were his patients.
At least one other lawsuit involving care by Veizaga-Mendez at the hospital is pending. James Marshall, 61, of Benton, Ky., died of a blood infection in July 2007, six days after Veizaga-Mendez performed a lymph node biopsy. His widow, Darla Marshall, is seeking $10 million in damages.
Veizaga-Mendez, who is not listed as a defendant in the lawsuits, has no listed telephone number and has not responded to repeated messages left by the AP at a Massachusetts home listed as an address for his wife.
Copyright 2008 The Associated Press.
Tests start on US-backed drug stress disorder
Date: 11/3/2008 2:50 PM
Tests start on US-backed drug stress disorder
BASEL, Switzerland (AP) — Clinical trials have begun on a new U.S-backed drug to treat the debilitating feeling of heightened vigilance experienced by veterans with post-traumatic stress, Swiss-based pharmaceutical company Synosia said Monday.
The study is funded with $1.4 million from the U.S. Defense Department and will focus on veterans of the wars in Iraq and Afghanistan, Synosia said.
The company said it hopes the drug, called nepicastat, will help patients who have lost the ability to accurately assess danger, resulting in a constant sense of alertness.
The condition, known as hyperarousal, is one symptom of post-traumatic stress disorder. Others include sleeplessness, anger and withdrawal from friends and family.
Post-traumatic stress disorder affects people from all walks of life, but is particularly common in veterans. Some 40,000 U.S. troops have been diagnosed with the disorder since 2003.
Synosia said the clinical trial will be conducted by researchers at veterans medical centers in Tuscaloosa, Alabama; Houston; and Charleston, South Carolina.
Officials at the U.S. Defense Department and the Department of Veterans Affairs could not immediately be reached for comment.
Initial results about the effectiveness and tolerability of nepicastat are expected next spring, said Synosia spokesman Jan Gregor. Synosia is conducting separate trials to test whether nepicastat is effective as a treatment for cocaine abuse.
Nepicastat works by inhibiting the conversion of the brain chemical dopamine into an adrenaline-like compound called norepinephrine.
____
On the Net:
Synosia: http://www.synosia.com
Copyright 2008 The Associated Press.
Tests start on US-backed drug stress disorder
BASEL, Switzerland (AP) — Clinical trials have begun on a new U.S-backed drug to treat the debilitating feeling of heightened vigilance experienced by veterans with post-traumatic stress, Swiss-based pharmaceutical company Synosia said Monday.
The study is funded with $1.4 million from the U.S. Defense Department and will focus on veterans of the wars in Iraq and Afghanistan, Synosia said.
The company said it hopes the drug, called nepicastat, will help patients who have lost the ability to accurately assess danger, resulting in a constant sense of alertness.
The condition, known as hyperarousal, is one symptom of post-traumatic stress disorder. Others include sleeplessness, anger and withdrawal from friends and family.
Post-traumatic stress disorder affects people from all walks of life, but is particularly common in veterans. Some 40,000 U.S. troops have been diagnosed with the disorder since 2003.
Synosia said the clinical trial will be conducted by researchers at veterans medical centers in Tuscaloosa, Alabama; Houston; and Charleston, South Carolina.
Officials at the U.S. Defense Department and the Department of Veterans Affairs could not immediately be reached for comment.
Initial results about the effectiveness and tolerability of nepicastat are expected next spring, said Synosia spokesman Jan Gregor. Synosia is conducting separate trials to test whether nepicastat is effective as a treatment for cocaine abuse.
Nepicastat works by inhibiting the conversion of the brain chemical dopamine into an adrenaline-like compound called norepinephrine.
____
On the Net:
Synosia: http://www.synosia.com
Copyright 2008 The Associated Press.
